Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab emtansine
Sponsor: Jenny C. Chang, MD
Collaborators: Genentech, Inc.|The Methodist Hospital Research Institute